Jefferies Group's LCTX Position Overview
Jefferies Group (via Jefferies Financial Group Inc.) currently holds 44,192 shares of Lineage Cell Therapeutics, Inc. (LCTX) worth $69,823, representing 0.00% of the portfolio. First purchased in 2023-Q1, this short-term holding has been held for 5 quarters.
Based on 13F filings, Jefferies Group has maintained this position in LCTX for several quarters, showing initial confidence in the investment. Largest addition occurred in Q3 2025, adding 62,200 shares. Largest reduction occurred in Q2 2023, reducing 23,998 shares.
Analysis based on 13F filings available since 2013 Q2
Jefferies Group's Lineage Cell Therapeutics (LCTX) Holding Value Over Time
Track share changes against reported price movement
Quarterly Lineage Cell Therapeutics (LCTX) Trades by Jefferies Group
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | -14,898 | Reduce 25.21% | 44,192 | $1.58 |
| Q4 2025 | -3,110 | Reduce 5.00% | 59,090 | $1.67 |
| Q3 2025 | +62,200 | New Buy | 62,200 | $1.69 |
| Q2 2023 | -23,998 | Sold Out | 0 | $0.00 |
| Q1 2023 | +23,998 | New Buy | 23,998 | $1.50 |
Jefferies Group's Lineage Cell Therapeutics Investment FAQs
Jefferies Group first purchased Lineage Cell Therapeutics, Inc. (LCTX) in Q1 2023, acquiring 23,998 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Jefferies Group has held Lineage Cell Therapeutics, Inc. (LCTX) for 5 quarters since Q1 2023.
Jefferies Group's largest addition to Lineage Cell Therapeutics, Inc. (LCTX) was in Q3 2025, adding 62,200 shares worth $105,118.
According to the latest 13F filing for Q1 2026, Jefferies Group's firm, Jefferies Financial Group Inc., owns 44,192 shares of Lineage Cell Therapeutics, Inc. (LCTX), valued at approximately $69,823.
As of the Q1 2026 filing, Lineage Cell Therapeutics, Inc. (LCTX) represents approximately 0.00% of Jefferies Group's publicly disclosed stock portfolio, making it one of their key holdings.
Jefferies Group's peak holding in Lineage Cell Therapeutics, Inc. (LCTX) was 62,200 shares, as reported at the end of Q3 2025.